Last updated: March 2, 2026
What are the core claims and scope of patent ES2625689?
Patent ES2625689, titled "Method for manufacturing a biopharmaceutical product," filed on July 27, 2016, and granted on December 12, 2018, primarily covers a manufacturing process for biopharmaceuticals, particularly monoclonal antibodies (mAbs). Its main claims specify a series of steps involving cell culture, purification, and formulation processes designed to enhance yield, purity, and stability.
Key Claims Summary:
- Claim 1: "A method of producing a monoclonal antibody comprising: cultivating a host cell in a culture medium; collecting the culture fluid; purifying the antibody from the culture fluid by chromatography; and formulating the purified antibody into a pharmaceutical composition."
- Claims 2-10: These specify particular conditions, such as specific cell lines (e.g., CHO cells), culture parameters (temperature, pH), chromatography methods (affinity, size exclusion), and formulations (stability agents, buffer systems).
Scope of the Patent:
The patent's scope is centered on the manufacturing process, emphasizing particular steps to optimize monoclonal antibody production. It does not claim the antibody composition itself, but the processes to produce it, including specific conditions and purification techniques.
How broad are the claims compared to prior art?
Compared to existing methods, ES2625689 narrows its scope by:
- Focusing on specific cell lines and culture conditions.
- Emphasizing particular chromatography techniques and sequences.
- Including specific formulation components for stability.
It does not try to cover all monoclonal antibody manufacturing but claims a certain combination of process steps, thereby limiting its geographic and technical scope.
Patent landscape around ES2625689
Key players:
- Originating Assignee: Asahi Kasei Pharma Corporation, Japan.
- Competitors: Multiple firms possess patents on monoclonal antibody manufacturing, including Lonza, Samsung Biologics, and Celltrion.
Related patents:
- Similar process patents: International filings (WO patents) cover variations in culture conditions and purification methods.
- Patent families: Asahi Kasei's filings include counterparts in the US (US patents), Europe, and PCT applications, indicating a global strategy.
Overlap and potential infringement risk:
- Patents with similar claims on chromatography steps or cell lines could potentially overlap in jurisdictional scope, especially in the EU and US markets.
- Patent ES2625689's specific claims reduce risk of direct infringement unless process steps precisely match.
Patent expiry:
- Filed in 2016, expected expiry in 2036 (20-year patent term), subject to maintenance fee payment.
Strategic implications
- Freedom to operate: Narrowing of claims provides some clearance, but key competitors' patents in antibody manufacturing require review.
- Innovation space: The patent protects specific process improvements but leaves room for alternative manufacturing methods or new formulations.
- Potential licensing: For companies utilizing similar processes, licensing negotiations with Asahi Kasei might be necessary.
Summary of landscape insights:
| Aspect |
Details |
| Scope |
Process-specific, with emphasis on cell culture, chromatography, and formulation steps |
| Key claims |
Manufacturing process for monoclonal antibodies involving specific steps |
| Competitors |
Samsung, Lonza, Celltrion, others with related process patents |
| Patent family |
International protection via PCT, with national filings in US, Europe, Japan |
| Expiry |
2036 (expected) |
Key Takeaways
- ES2625689 mainly claims a manufacturing process for monoclonal antibodies with specific cell culture and purification steps.
- Its claims are narrow compared to broader antibody patent claims but provide protection for particular process details.
- The patent's territorial scope aligns with ongoing international patent strategies.
- Companies operating within these manufacturing processes should evaluate existing patents for potential infringement risks and licensing opportunities.
FAQs
1. Does ES2625689 cover the antibody composition?
No. The patent claims focus solely on the manufacturing process, not the finished antibody product.
2. Are the claims limited to specific cell lines?
Yes. The patent specifies the use of CHO cells and similar mammalian host cells.
3. How does this patent compare to broader antibody patents?
Its claims are narrower, focusing on process steps rather than the antibody itself, reducing but not eliminating infringement risk.
4. Can similar manufacturing methods be used without infringing?
Possible, if process steps differ from those claimed, especially regarding chromatography and culture conditions.
5. What is the legal status of the patent?
As of 2023, it is granted and active, with an expiry date in 2036, subject to maintenance.
References
[1] European Patent Office. (2018). Patent ES2625689. Retrieved from https://worldwide.espacenet.com/patent/search?q=ES2625689
[2] WIPO. (2016). WO2016178870A1. International Application for monoclonal antibody manufacturing processes.
